The popularity of Viagra initially sparked a period of growth for major pharmaceutical companies, but recent changes present a uncertain scenario for shareholders. Lower-cost competitors are eroding earnings, and persistent patent challenges add further risk to the equation. While specific companies could still gain from adjacent services, the gene